Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?
ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.
Zacks Investment Research7/29/2026Neutral
ZBH
Zimmer Biomet Holdings IncNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$17.81B
P/E Ratio
23.85
EPS
$3.86
Beta
0.46
52W High
$107.16
52W Low
$78.91
50-Day MA
$87.82
200-Day MA
$91.13
Dividend Yield
1.05%
Profit Margin
9.05%
Forward P/E
10.94
PEG Ratio
0.65
About Zimmer Biomet Holdings Inc
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Fundamentals
| Revenue (TTM) | $8.41B |
| Gross Profit (TTM) | $5.90B |
| EBITDA | $2.58B |
| Operating Margin | 19.70% |
| Return on Equity | 6.07% |
| Return on Assets | 4.10% |
| Revenue/Share (TTM) | $42.68 |
| Book Value | $65.53 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | 2.12 |
| EV/Revenue | 2.94 |
| EV/EBITDA | 10.71 |
| Quarterly Earnings Growth (YoY) | 34.10% |
| Quarterly Revenue Growth (YoY) | 9.30% |
| Shares Outstanding | $193.46M |
| Float | $192.93M |
| % Insiders | 0.15% |
| % Institutions | 106.31% |
Historical Volatility
HV 10-Day
35.84%
HV 20-Day
43.21%
HV 30-Day
38.52%
HV 60-Day
32.08%
HV Rank
76.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($98.60 target)
2
Strong Buy6
Buy17
Hold1
SellLatest News
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research7/21/2026Positive
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
WARSAW, Ind., July 14, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the company's Asia Pacific Region, effective immediately.
PRNewsWire7/14/2026Neutral
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
WARSAW, Ind., July 13, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be webcast on Wednesday, August 5, 2026 at 8:30 a.m.
PRNewsWire7/13/2026Neutral
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
Zimmer Biomet ZBH appears well positioned for growth in the coming quarters, supported by the continued execution of its market strategies centered on People and Culture, Operational Excellence, and Innovation and Diversification pillars. Growth in the knee business revenues is backed by the robust adoption of its cementless offerings.
Zacks Investment Research7/10/2026Positive
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research7/2/2026Positive
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Zacks Investment Research7/1/2026Neutral
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
ISRG stands out over ZBH as stronger revenue growth, rising procedure demand, and expanding AI-driven innovation support better upside in 2026.
Zacks Investment Research6/24/2026Positive
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research6/18/2026Positive
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research6/16/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZBH and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026